The study by McGilvray et al. also indicated that patients with ovarian cancer with high expression of ULBP1 had a worse survival than those patients with no expression of ULBP1 (disease-specific survival: 14 months vs. 30 months) (McGilvray et al., 2010). Here, ULBP1 is linked to ovarian carcinoma.